Literature DB >> 11712747

Eotaxin and asthma.

J E Pease1, T J Williams.   

Abstract

Eotaxin is a small protein that is produced in the lungs of asthmatic patients and is a potent chemoattractant for eosinophils. Eotaxin, a CC chemokine, stimulates the migration of eosinophils from the small blood vessels in the lungs by acting on the CC chemokine receptor CCR3, which is located on the leukocyte cell surface. In the past year, three low molecular weight compounds have been developed that can block this receptor. Such compounds may be developed into orally available drugs aimed at preventing eosinophil recruitment and, hence, the pathogenesis associated with the activation of these cells within the lung tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712747     DOI: 10.1016/s1471-4892(01)00044-3

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  30 in total

1.  B lymphocytes regulate airway granulocytic inflammation and cytokine production in a murine model of fungal allergic asthma.

Authors:  Sumit Ghosh; Scott A Hoselton; Scott V Asbach; Breanne N Steffan; Steve B Wanjara; Glenn P Dorsam; Jane M Schuh
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  The attraction of chemokines as a target for specific anti-inflammatory therapy.

Authors:  James E Pease; Timothy J Williams
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  A hexanucleotide repeat upstream of eotaxin gene promoter is associated with asthma, serum total IgE and plasma eotaxin levels.

Authors:  Jyotsna Batra; Reenu Rajpoot; Jasmine Ahluwalia; Satish K Devarapu; Surendra K Sharma; Amit K Dinda; Balaram Ghosh
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

4.  Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma.

Authors:  Sara C Sebag; Olha M Koval; John D Paschke; Christopher J Winters; Omar A Jaffer; Ryszard Dworski; Fayyaz S Sutterwala; Mark E Anderson; Isabella M Grumbach
Journal:  JCI Insight       Date:  2017-02-09

5.  Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma.

Authors:  Angie S Morris; Sara C Sebag; John D Paschke; Amaraporn Wongrakpanich; Kareem Ebeid; Mark E Anderson; Isabella M Grumbach; Aliasger K Salem
Journal:  Mol Pharm       Date:  2017-05-09       Impact factor: 4.939

6.  Allergic challenge-elicited lipid bodies compartmentalize in vivo leukotriene C4 synthesis within eosinophils.

Authors:  Adriana Vieira-de-Abreu; Edson F Assis; Gleice S Gomes; Hugo C Castro-Faria-Neto; Peter F Weller; Christianne Bandeira-Melo; Patrícia T Bozza
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-09       Impact factor: 6.914

Review 7.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

8.  PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.

Authors:  Raffaela Zaffini; Rosanna Di Paola; Salvatore Cuzzocrea; Marta Menegazzi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-07       Impact factor: 3.000

9.  Immune-Associated Proteins Are Enriched in Lung Tissue-Derived Extracellular Vesicles during Allergen-Induced Eosinophilic Airway Inflammation.

Authors:  Cecilia Lässer; Yasunari Kishino; Kyong-Su Park; Ganesh Vilas Shelke; Nasibeh Karimi; Shintaro Suzuki; Lilit Hovhannisyan; Madeleine Rådinger; Jan Lötvall
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

10.  Obesity increases eosinophil activity in asthmatic children and adolescents.

Authors:  Milena Baptistella Grotta; Dalize M Squebola-Cola; Adyleia A D C Toro; Maria Angela G O Ribeiro; Silvia B Mazon; Jose D Ribeiro; Edson Antunes
Journal:  BMC Pulm Med       Date:  2013-06-18       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.